Ionis Pharmaceuticals Inc. Common Stock vs ThredUp Inc — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B), while ThredUp Inc trades at $2.2 (market cap $303.38M). The key difference: Ionis Pharmaceuticals Inc. Common Stock is far larger — about 23.2× ThredUp Inc's market cap, and Ionis Pharmaceuticals Inc. Common Stock is more actively traded (2,977,440 versus 1,426,025). Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and ThredUp Inc for 29 Days on average.
| IONS | TDUP | |
|---|---|---|
Market Cap | $7.04B | $303.38M |
Volume | 2,977,440 | 1,426,025 |
Sector | Health | Consumer Cyclical |
52-Week High | $86.50 | $9.38 |
52-Week Low | $42.38 | $2.12 |
Typical Hold Time | 0 Days | 29 Days |
Enterprise Value | $6.60B | $301.56M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ThredUp (TDUP) trades at $2.2, down 11.29% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed EPS estimates and cut full-year revenue guidance. Cash flow from operations improved to $10.65 million in 2025, though net income remains negative. Analyst consensus is 57% buy, with no sell ratings, but recent news highlights promotional headwinds and a securities investigation.
The outlook is cautious; revenue growth and high gross margins are positives, but persistent losses, weak guidance, and legal risks pose challenges. The stock's low price-to-sales ratio of 0.88 may attract value investors, yet profitability concerns and negative ROE of -36.76% underscore significant execution risk. Investors should weigh strong analyst support against fundamental weaknesses and market sentiment shifts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →